Ellevest Inc
REGN icon

Ellevest Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Ellevest Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$447K Buy
589
+27
+5% +$20.4K 0.05% 271
2026
Q2 		$353K Sell
562
-69
-11% -$47K 0.04% 323
2026
Q1 		$488K Sell
631
-278
-31% -$213K 0.07% 237
2025
Q4 		$702K Sell
909
-202
-18% -$137K 0.1% 152
2025
Q3 		$625K Buy
1,111
+260
+31% +$147K 0.09% 168
2025
Q2 		$447K Buy
851
+464
+120% +$259K 0.07% 217
2025
Q1 		$245K Sell
387
-155
-29% -$107K 0.02% 334
2024
Q4 		$386K Buy
542
+202
+59% +$170K 0.02% 256
2024
Q3 		$357K Buy
340
+33
+11% +$36.7K 0.02% 288
2024
Q2 		$323K Sell
307
-6
-2% -$5.82K 0.02% 305
2024
Q1 		$301K Buy
313
+4
+1% +$3.8K 0.02% 311
2023
Q4 		$271K Sell
309
-75
-20% -$61.8K 0.02% 313
2023
Q3 		$316K Sell
384
-232
-38% -$182K 0.02% 255
2023
Q2 		$443K Buy
616
+127
+26% +$97.9K 0.03% 177
2023
Q1 		$402K Buy
489
+81
+20% +$61.1K 0.03% 180
2022
Q4 		$294K Buy
408
+11
+3% +$8.12K 0.02% 235
2022
Q3 		$273K Sell
397
-43
-10% -$27.1K 0.03% 207
2022
Q2 		$260K Buy
440
+6
+1% +$3.9K 0.02% 232
2022
Q1 		$303K Buy
434
+207
+91% +$131K 0.03% 235
2021
Q4 		$143K Buy
227
+1
+0.4% +$615 0.01% 342
2021
Q3 		$137K Buy
226
+33
+17% +$20.5K 0.01% 343
2021
Q2 		$108K Buy
193
+178
+1,187% +$90.2K 0.01% 361
2021
Q1 		$7K Sell
15
-175
-92% -$85.2K ﹤0.01% 850
2020
Q4 		$92K Buy
190
+38
+25% +$20.5K 0.01% 329
2020
Q3 		$85K Sell
152
-4
-3% -$2.42K 0.02% 297
2020
Q2 		$97K Buy
156
+127
+438% +$72.1K 0.02% 215
2020
Q1 		$14K Buy
29
+18
+164% +$7.42K ﹤0.01% 493
2019
Q4 		$4K Buy
11
+2
+22% +$673 ﹤0.01% 622
2019
Q3 		$2K Buy
+9
New +$2.66K ﹤0.01% 348

Other funds holding REGN

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ellevest Inc's REGN Position: Q3 2026 in Review

Ellevest Inc increased its Regeneron Pharmaceuticals (REGN) stake by 4.8% in Q3 2026, buying an estimated $20.4K and bringing the position to 589 shares worth $447K. The position accounts for 0.05% of the portfolio, ranked #271.

Ellevest Inc first reported a position in REGN in Q3 2019 and has held it in 29 quarters since. The position peaked at $702K in Q4 2025. 1,011 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Ellevest Inc held 589 shares of Regeneron Pharmaceuticals worth $447K as of Q3 2026.
  • Ellevest Inc bought 27 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $20.4K.
  • Regeneron Pharmaceuticals made up 0.05% of Ellevest Inc's portfolio in Q3 2026, its #271 holding.
  • Ellevest Inc first reported a position in Regeneron Pharmaceuticals in Q3 2019 and has held it in 29 quarters since.
  • Ellevest Inc's Regeneron Pharmaceuticals position peaked at $702K in Q4 2025.
  • 1,011 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Ellevest Inc's 13F filing for Q3 2026, filed 10 Nov 2026.